Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public markets pitfalls.
Today, we look at Mind Cure Health (MCUR.C) a Canadian-based psychedelics company carving an innovative slice of the psychedelics space with its ground-breaking iSTRYM digital platform, novel synthesis of the ibogaine molecule and its leading-edge MDMA-assisted therapy protocol for the treatment of Hypoactive Sexual Desire Disorder. A reasonably priced ground-floor investment opportunity with plenty of upside.
Enjoy!
